Get the app
US › Healthcare

Opus Genetics, Inc. (IRD)

US · Healthcare · Biotechnology

$3.84-5.19%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$755,000
Revenue YoY
-73.8%
Net profit
$-8.1M
EPS
$-0.14
EPS estimate
$-0.15
Net margin
-1,072.6%

EPS came in at -0.14 against a street estimate of -0.15 — a beat of 6.7%.

Key statistics

Market cap
$386.0M
Forward P/E
12.0
P/B
23.82
Book value
$-0.16
EPS (TTM)
$-1.27
52-week high
$7.07
52-week low
$1.70
50-day MA
$4.46
200-day MA
$4.06
Beta
0.62

Analyst view

Analysts rate Opus Genetics, Inc. a strong buy (18 buy, 0 hold, 0 sell out of 18) with an average price target of $13.41.

Shareholding

Insiders
12.23%
Institutions
69.27%

Largest institutional holders

FundStake
Nantahala Capital Management, LLC7.36%
Caligan Partners LP7.30%
Adage Capital Partners Gp LLC7.25%
BIOS CAPITAL MANAGEMENT, LP4.43%
BlackRock Inc3.75%
Balyasny Asset Management LLC3.71%
Vanguard Capital Management, LLC3.56%
Boxer Capital Management, LLC3.38%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Opus Genetics, Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.